Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia
about
Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysisTreatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychoticsRealities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.G protein-coupled receptors in major psychiatric disorders.Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects predictionThe promise and reality of pharmacogenetics in psychiatryPharmacogenetics of antipsychotic-induced side effectsCritical evaluation of cognitive dysfunctions as endophenotypes of schizophrenia.Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update.Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.Genetic polymorphisms of 5-HTT and DAT but not COMT differentially affect verbal and visuospatial working memory functioning.Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population.Increased Nigral SLC6A3 Activity in Schizophrenia Patients: Findings From the Toronto-McLean CohortsA preclinical and clinical rationale for quetiapine in mood syndromes.Pharmacogenetics in psychiatry: are we ready for widespread clinical use?The potential role of dopamine D₃ receptor neurotransmission in cognition.Factors associated with response to clozapine in schizophrenia: a review.DAT by perceived MC interaction on human prefrontal activity and connectivity during emotion processing.Dopamine transporter polymorphism modulates oculomotor function and DAT1 mRNA expression in schizophrenia.Review: The biological basis of antipsychotic response in schizophrenia.Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.Pharmacogenetic considerations in the treatment of psychiatric disorders.Pharmacogenomics of antipsychotics efficacy for schizophrenia.Genetics of antipsychotic-induced side effects and agranulocytosis.Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.Pharmacogenetics of response to antipsychotics in patients with schizophrenia.Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia.Pharmacogenetics of clinical response to risperidone.Pharmacogenetics in schizophrenia: a review of clozapine studies.Individualizing clozapine and risperidone treatment for schizophrenia patients.Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature.A variable number of tandem repeats in the 3'-untranslated region of the dopamine transporter modulates striatal function during working memory updating across the adult age span.Dopamine D3 Receptors Inhibit Hippocampal Gamma Oscillations by Disturbing CA3 Pyramidal Cell Firing Synchrony.Acute treatment response and its predictors in patients with first-episode psychosis in Iran.A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms.DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents.Impact of five SNPs in dopamine-related genes on executive function.Variants in COMT and DBH influence on response inhibition ability in Chinese Han females.Epistasis between COMT Val158Met and DRD3 Ser9Gly polymorphisms and cognitive function in schizophrenia: genetic influence on dopamine transmission.Investigation of possible association between Ser9Gly polymorphism of the D3 dopaminergic receptor gene and response to typical antipsychotics in patients with schizophrenia.
P2860
Q24600775-490F7E15-1D8A-4741-BB10-C992839BCE90Q28079065-AA9EDA4D-7B02-4727-B31F-3249260D7EB6Q34131354-A11DA7CC-CF1F-423E-A0DD-E08E2A5EFD22Q34578414-D9E479BA-E08C-49B3-A68F-CEC17EFF9FF6Q34676533-1E18A26D-B474-472D-9A2C-D7AFCA567363Q35226451-DEE7CEDF-2BB6-4FF0-A2BE-28349DA59926Q35237129-78495E54-5614-4B5C-AF08-45D83F472707Q35826356-FACA3C1C-F6B3-4CA9-A035-7DEC2C1361A1Q35873691-4EB4A3D7-077E-4E70-8854-85A2BBC3D4BAQ36120821-D9F8355F-55B8-4425-88CE-B88CD308DFC0Q36377442-B080FFB1-C47C-47AE-B2DD-30B14C4F78E8Q36747019-1D20D6C9-A97A-4BDA-82FE-DE4DD3159F4AQ36817270-03678E6E-0DA6-4FC4-833D-D1C9C30919D9Q36847279-73C8BC1B-6EC5-4733-A9A2-70F1A0224504Q37076472-9ABD25FA-2852-46BC-B256-C63E4FC00978Q37106827-B8E6827E-4566-4327-87A3-39BEC3128000Q37300007-41C42FBB-8C0A-4385-B24A-1B296F7E1406Q37318439-30199C8A-FC2B-4B6E-BF1E-E697B0BB7FACQ37415205-C54A5167-7B73-4CCE-81F7-9B29081DF626Q37638930-D24E7692-F68B-405C-A7FC-4B2EB710E68DQ37678047-09CBBE2B-D60C-45FB-AC0A-6261C0568856Q37681573-ACF4A751-3D36-4714-82EB-49769E924CA7Q37832287-1A848C7D-B243-4EA6-B054-FBB823F69848Q37845227-6B0ED1D6-E61A-4578-8073-CB81EB558986Q37926893-01AE2365-BEC6-449F-ACAB-6DD5FF8D7E56Q37952823-9091B03A-8022-42A4-9C15-48B6803278A0Q37960512-5413795A-302E-4BA6-B5BA-9E72BEF388C4Q38074712-37C8BB30-21A0-4353-8D4F-10E4D230D990Q38154175-0441BE6F-5409-43C1-8A4A-FF39C1C1E4B7Q38170458-3C06940E-B4E2-450B-974A-7B15837D7CE7Q38254316-8481DA04-EBA3-481F-9B36-A385E011CB39Q40915102-B52CCF9A-49B2-4899-BFD8-6636797F67F8Q41954081-3B176B45-DC7E-4BED-B14E-854E9F8A71E9Q43513969-C6D059D9-347F-4ABC-8EB3-2BBBC5F7B319Q45977566-C60D775E-0EF0-4FA8-AC2A-FBB1534431A7Q46693337-B4B239E1-6858-45AD-BCE6-4D90511C56E9Q48550764-2BAC711B-0275-444E-B62D-D3CEF5F23394Q51448314-F8FBC4F3-A7CB-4686-AD69-6A272B5FC1DDQ53349063-251C68CF-C0A5-4C79-976A-B93CB7949C1CQ54570430-21E5E72A-5F55-4BFF-81DA-5D45D9445DB1
P2860
Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Role of dopamine D3 receptor ( ...... in patients with schizophrenia
@ast
Role of dopamine D3 receptor ( ...... in patients with schizophrenia
@en
Role of dopamine D3 receptor ( ...... in patients with schizophrenia
@en-gb
Role of dopamine D3 receptor ( ...... in patients with schizophrenia
@nl
type
label
Role of dopamine D3 receptor ( ...... in patients with schizophrenia
@ast
Role of dopamine D3 receptor ( ...... in patients with schizophrenia
@en
Role of dopamine D3 receptor ( ...... in patients with schizophrenia
@en-gb
Role of dopamine D3 receptor ( ...... in patients with schizophrenia
@nl
prefLabel
Role of dopamine D3 receptor ( ...... in patients with schizophrenia
@ast
Role of dopamine D3 receptor ( ...... in patients with schizophrenia
@en
Role of dopamine D3 receptor ( ...... in patients with schizophrenia
@en-gb
Role of dopamine D3 receptor ( ...... in patients with schizophrenia
@nl
P2093
P2860
P921
P3181
P356
P1476
Role of dopamine D3 receptor ( ...... in patients with schizophrenia
@en
P2093
Agnes Rimanóczy
Anna Juhász
Csongor Czimmer
György Szekeres
István Szendi
Szabolcs Kéri
Zoltán Janka
P2860
P3181
P356
10.1002/AJMG.B.20045
P407
P577
2004-01-01T00:00:00Z